MSLN Fc Chimera Protein, Cynomolgus,specification,price,image-Bio-Equip in China

Product Detail
Company Profile

Product Specification

Species	Cynomolgus
Synonyms	CAK1; Mesothelin; MPF; MPFSMRP; SMR
Accession	A0A2K5TW94(UniParc.UPI000C7396BF)
Amino Acid Sequence	Asp296-Gly580, with C-terminal Fc
Expression System	HEK293
Molecular Weight	68-80kDa (Reducing)
Purity	>95% by SDS-PAGE & SEC-HPLC
Endotoxin	<0.1EU/μg
Conjugation	Unconjugated
Tag	Human Fc Tag
Physical Appearance	Lyophilized Powder
Storage Buffer	PBS, PH7.4, 5% trehalose，5% mannitol
Reconstitution	Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage	· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles.
Reference	Chang K. et al. (1996) Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. PNAS. 93(1): 136-140. Liu X. et al. (2020) Multiple proteases are involved in mesothelin shedding by cancer cells. Commun Biol. 3: 728.

Background

Mesothelin (MSLN) is also known as CAK1 antigen, Pre-pro-megakaryocyte potentiating factor, which belongs to the mesothelin family. Mesothelin/MSLN can be proteolytically cleaved into the following two chains by a furin-like convertase: Megakaryocyte-potentiating factor (MPF) and the cleaved form of mesothelin. Both MPF and the cleaved form of mesothelin are N-glycosylated. Mesothelin/MSLN can interacts with MUC16. The membrane-anchored form of MSLN may play a role in cellular adhesion. MPF potentiates megakaryocyte colony formation in vitro. Mesothelin (MSLN) is a lineage restricted cell surface protein expressed in about 30% of human cancers and high MSLN expression is associated with poor survival in several different cancers. The restricted expression of MSLN in normal tissue and its frequent expression in cancers make MSLN an excellent target for antibody-based therapies.